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A B S T R A C T
Background
Chronic neutrophilic inflammation, in both the presence and absence of infection, is a feature of bronchiectasis in adults and children.
The anti-inflammatory properties of non-steroid anti-inflammatory drugs (NSAIDs)may be beneficial in reducing airway inflammation,
thus potentially improving lung function and quality of life in patients with bronchiectasis.
Objectives
To evaluate the efficacy of inhaled NSAIDs in the management of non-cystic fibrosis bronchiectasis in children and adults:
• during stable bronchiectasis; and
• for reduction of:
severity and frequency of acute respiratory exacerbations; and
long-term pulmonary decline.
Search methods
We searched the Cochrane Airways Group Trials Register, which includes reports identified from the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Cumulative Index toNursing and AlliedHealth Literature (CINAHL).
We also searched the trial registry ClinicalTrials.gov and the World Health Organization (WHO) trial portal. We carried out the latest
searches on 22 September 2015.
Selection criteria
All randomised controlled trials comparing inhaled NSAIDs versus a control (placebo or usual treatment) in children or adults with
bronchiectasis not related to cystic fibrosis.
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Data collection and analysis
We reviewed the results of searches against predetermined criteria for inclusion.
Main results
One small, short-term trial was eligible for inclusion. We included this study of 25 adults with chronic lung disease (only 32% of
people included in the trial had bronchiectasis), as the other conditions were linked to development of bronchiectasis, and all were
characterised by chronic sputum production. We were not able to obtain separate data for people with a diagnosis of bronchiectasis.
We judged that the study was at a high risk of selection bias.
The primary outcome (mean difference in control of bronchiectasis severity, quality of life (Qol), cough scores) was not reported in
the included study. The single trial in adults reported a significant reduction in sputum production over 14 days for the treatment
group (inhaled indomethacin) compared with the placebo group (mean difference (MD) -75.00 g/day; 95% confidence interval (CI)
-134.61 to -15.39) and a significant improvement in the Borg Dyspnoea Scale score (MD -1.90, 95% CI -3.15 to -0.65). We noted
no significant differences between groups in lung function or blood indices and no reported adverse events.
Authors’ conclusions
Nonew studies of adults or children have been conducted since the last version of this review was published. Therefore, final conclusions
have not changed. Current evidence is insufficient to support or refute the use of inhaled NSAIDs for themanagement of bronchiectasis
in adults or children. One small trial reported a reduction in sputum production and improved dyspnoea among adults with chronic
lung disease who were treated with inhaled indomethacin, indicating that additional studies on the efficacy of NSAIDs for treatment
of patients with bronchiectasis are warranted.
P L A I N L A N G U A G E S U M M A R Y
Inhaled non-steroid anti-inflammatories (NSAIDs) for children and adults with bronchiectasis
People with bronchiectasis experience chronic inflammation of the lungs. Anti-inflammatory effects of inhaled non-steroid anti-
inflammatory drugs (NSAIDs) may be beneficial for patients with bronchiectasis. However, short-term and long-term benefits in adults
and children must be investigated, in addition to potential side effects of NSAIDs used over the long term.
Results
We included one small study on 25 people with chronic lung disease. Of those 25, only eight people had bronchiectasis. Other
individuals had chronic bronchitis of diffuse panbronchiolitis and were at risk for bronchiectasis. However, we must remember when
interpreting the results that not all study participants had bronchiectasis.
Overall, the small study reported improvement in sputum production and dyspnoea (shortness of breath) in adults with chronic lung
disease (chronic bronchitis, bronchiectasis or diffuse panbronchiolitis) who received inhaled indomethacin compared with placebo.
Researchers observed no significant improvement in lung function (forced expiratory volume in one second (FEV1) and vital capacity
(VC)) and reported no adverse events.
Conclusions
The small scale of this study and collective analysis of data from the three disease states made it difficult for review authors to draw
solid conclusions on the benefit of using NSAIDs to treat adults with bronchiectasis. Review authors identified no studies examining
the use of NSAIDs in children with bronchiectasis.
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B A C K G R O U N D
Description of the condition
Bronchiectasis is increasingly recognised as a major cause of res-
piratory morbidity, especially in developing countries (Karadag
2005; Karakoc 2001) and in pockets of affluent countries (Chang
2008). The underlying aetiology of bronchiectasis varies; it may
follow recurrent respiratory infection or may occur secondary to
rare immune deficiencies. However, bronchiectasis is also a com-
mon pathway for a variety of diseases. Thus, the presence of
bronchiectasis is increasingly recognised in common (e.g. chronic
obstructive pulmonary disease (COPD) (O’Brien 2000)) and un-
common respiratory diseases (e.g. bronchiolitis obliterans, sar-
coidosis (Lewis 2002)) as well as in non-primary respiratory
(e.g. autoimmune) diseases. When bronchiectasis is present along
with another underlying disorder, morbidity and mortality of the
underlying disease are increased (Keistinen 1997; Lewis 2002).
For example, bronchiectasis has been reported in 29% to 50%
(O’Brien2000) of cohortswithCOPDandwhenpresent increases
the severity and frequency (Gursel 2006) of respiratory exacerba-
tions.
Dominant symptoms and signs of bronchiectasis include produc-
tive or wet cough, dyspnoea on exertion and other respiratory
signs (e.g. clubbing, chest wall deformity, respiratory noises such
as wheeze or crepitations on auscultation). Pulmonary declinemay
occur over the long-term (Keistinen 1997). Also, as with COPD,
children and adults with bronchiectasis suffer from recurrent acute
exacerbations, some of which require treatment in the hospital
(Chang 2008). Effective management regimens for bronchiectasis
improve quality of life (Courtney 2008; Martinez-Gracia 2005;
Muthalithas 2008) and could reduce the frequency or severity of
respiratory exacerbations (Cymbala 2005) and/or long-term pul-
monary decline (Chang 2008). Thus, management of the symp-
toms and severity of bronchiectasis is important.
Description of the intervention
Non-steroid anti-inflammatory drugs (NSAIDs) are a class of
medications that act as non-selective inhibitors of the enzyme cy-
clo-oxygenase, inhibiting both cyclo-oxygenase-1 (COX-1) and
cyclo-oxygenase-2 (COX-2) isoenzymes. NSAIDs have analgesic,
antipyretic and anti-inflammatory effects and reduce pain, fever
and inflammation. NSAIDs are usually given orally, but the in-
haled formulation has been used in people with bronchorrhoea,
a feature present in many patients with bronchiectasis (Tamaoki
1992).
How the intervention might work
Cole’s ’vicious circle hypothesis’ indicates that microbial colonisa-
tion/infection is important in the pathophysiology of bronchiec-
tasis, as it leads to bronchial obstruction and an abnormal or exag-
gerated inflammatory response (Cole 1986). Anti-inflammatory
drugs may reduce the inflammatory cascade, thus ameliorating
symptoms and reducing long-term pulmonary decline.
As the airways of patients with bronchiectasis show intense neu-
trophilic inflammation (Cole 1986), the anti-inflammatory ef-
fects of NSAIDs may have a beneficial effect for patients with
bronchiectasis. “Blockade of cyclooxygenase pathway with in-
domethacin could decrease respiratory tract fluid and mucus by
inhibiting chloride secretion and glandular secretion and by en-
hancing Na (sodium) absorption across airway mucosa” (Tamaoki
1992). Animal studies have shown that pretreatment with inhaled
indomethacin protects the airway from distilled water and ozone,
and this increases lung resistance through swelling of airway ep-
ithelial cells (Mochizuki 2002).
Why it is important to do this review
Although NSAIDs may have potential benefits for those with
bronchiectasis, oral NSAIDs are associated with several adverse
events, particularly of the gastrointestinal tract (Behrman 2003).
NSAIDs may be better tolerated when inhaled; however, tran-
sient upper airway irritation has been reported (Ong 2004; Sestini
1999). It is therefore important to assess additional side effects
associated with inhalation of NSAIDs.
Evidence suggests that NSAIDs may prevent pulmonary deterio-
ration in people with mild lung disease due to cystic fibrosis (CF)
(Lands 2013). However, extrapolation of treatment for individu-
als with CF to those with non-CF bronchiectases may be harmful
(e.g. recombinant human DNase efficacious in CF causes harm
in non-CF bronchiectasis (Crockett 2014)). Thus, a systematic
review on the efficacy of inhaled NSAIDs in the treatment of chil-
dren and adults with bronchiectasis could guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy of inhaled NSAIDs for the management
of non-cystic fibrosis bronchiectasis in children and adults:
• during stable bronchiectasis; and
• for reduction of:
◦ severity and frequency of acute respiratory
exacerbations; and
◦ long-term pulmonary decline.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) comparing
inhaled NSAIDs versus a control (placebo or usual treatment) in
peoplewith bronchiectasis.Weplanned to include studies reported
as full text, those published as abstract only and unpublished data.
Types of participants
We included studies involving children or adults with a diagnosis
of bronchiectasis (defined clinically or radiologically).We excluded
studies of people with cystic fibrosis and COPD.
Types of interventions
We included studies comparing all types of inhaledNSAIDs (study
group) versus usual care or placebo (control group). We included
studies with co-interventions provided they were not part of the
randomly assigned treatment and both groups had equal access to
the co-interventions.
Types of outcome measures
Primary outcomes
• For short-term effectiveness (≤ 12 months): mean
difference in control of bronchiectasis severity (quality of life
(QOL), cough scores).
• For medium- to long-term outcomes (> 1 year):
difference in lung function data (forced expiratory volume in one
second (FEV1) % predicted).
Secondary outcomes
Short-term effectiveness (≤ 12 months)
• Total number of days with respiratory symptoms.
• Mean difference in lung function indices (spirometry, other
lung volumes, airway hyper-responsiveness).
• Proportions of participants who had respiratory
exacerbations and/or hospitalisations.
• Total number of hospitalised days.
• Mean difference in other objective indices (e.g. airway
markers of inflammation, exhaled nitric oxide).
• Proportions experiencing adverse effects of the intervention
(e.g. gastritis, haematemesis, ecchymoses).
• Serious adverse events (e.g. haemoptysis, bronchospasm).
Medium- to long-term outcomes (> 1 year)
• Radiology scores (high-resolution computed tomography
scans or chest radiograph).
• Clinical indices of control of bronchiectasis severity (e.g.
QOL, cough diary, Likert scale, visual analogue scale, level of
interference of cough).
• Mortality.
• Proportions experiencing adverse effects of the intervention
(e.g. gastric bleeding, gastritis, haematemesis, cardiac events).
• Serious adverse events (e.g. haemoptysis, bronchospasm).
Search methods for identification of studies
Electronic searches
Search methods used in the previous version of this review are
detailed in Appendix 1. The previously published version included
searches up to October 2009. The search period for this update is
October 2009 through September 2015.
For this update, we identified trials from the Cochrane Air-
ways Group Specialised Register (CAGR), which is maintained
by the Trials Search Co-ordinator for the Group. The Register
contains trial reports identified through systematic searches of
bibliographic databases, including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
the Cumulative Index to Nursing and Allied Health Literature
(CINAHL), the Allied and Complementary Medicine Database
(AMED) and PsycINFO, and by handsearching of respiratory
journals and meeting abstracts (see Appendix 2 for details). We
searched all records in the CAGR using the search strategy pro-
vided in Appendix 3.
We also searched ClinicalTrials.gov (www.ClinicalTrials.gov)
and the World Health Organization (WHO) trials portal (
www.who.int/ictrp/en/). We searched all databases from their in-
ception to the present, and we imposed no restriction on language
of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for trial information. We planned to communicate
with the authors of trials included in the review, when necessary.
We searched for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
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From the title, abstract or descriptors, two review authors (SP,
AC) independently reviewed the literature searches to identify po-
tentially relevant trials for full review. We conducted searches of
bibliographies and texts to identify additional studies. From the
full text and on the basis of specified criteria, the same two review
authors independently selected trials for inclusion. The review au-
thors (SP, AC) reported no disagreement on the selection of trials.
We documented ineligible studies in the table, Characteristics of
excluded studies.
Data extraction and management
We reviewed trials that satisfied the inclusion criteria for the fol-
lowing information: study setting; year of study; source of fund-
ing; patient recruitment details (including number of eligible par-
ticipants); inclusion and exclusion criteria; other symptoms; ran-
domisation and allocation concealment methods; numbers of par-
ticipants randomly assigned; blinding (masking) of participants,
care providers and outcome assessors; dose and type of interven-
tion; duration of therapy; co-interventions; numbers of partici-
pants not followed up; reasons for withdrawal from study protocol
(clinical events, side effects, refusal and other); details on side ef-
fects of therapy; and whether intention-to-treat analyses were used
when possible. We would have extracted data on the outcomes de-
scribed previously. When required, we planned to obtain further
information from the study authors.
Assessment of risk of bias in included studies
To assess risk of bias, two review authors (SP, AC) independently
assessed the quality of the studies on the basis of the criteria out-
lined in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). Review authors assessed risk of bias accord-
ing to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
This is briefly described in the following sections.
Allocation concealment
• Adequate: if allocation of participants involved a central
independent unit, an on-site locked computer, identical
appearing numbered drug bottles or containers prepared by an
independent pharmacist or investigator or sealed opaque
envelopes.
• Unclear: if the method used to conceal allocation was not
described.
• Inadequate: if the allocation sequence was known to
investigators who assigned participants, or if the study was quasi-
randomised.
Random sequence generation
1. Adequate: if methods of randomisation included using a
random number table, computer-generated lists or similar
methods.
2. Unclear: if the trial was described as randomised, but the
methods used to allocate participants to treatment groups were
not described.
3. Inadequate: if methods of randomisation included
alternation, use of case record numbers, date of birth or day of
the week and any procedure that was entirely transparent before
allocation.
Blinding of participants and personnel
1. Blinding of clinician (person delivering treatment) to
treatment allocation.
2. Blinding of participant to treatment allocation.
3. Blinding of outcome assessor to treatment allocation.
Follow-up
Weplanned to grade numbers and reasons for drop-outs and with-
drawals in each intervention group.
Measures of treatment effect
We analysed data using RevMan 2014. We analysed continuous
data as mean differences (MDs) with 95% confidence intervals
(CIs). If studies reported outcomes by usingdifferentmeasurement
scales, we planned to use standardised mean differences (SMDs).
For dichotomous variables, we planned to analyse data as odds
ratios (ORs) with 95% CIs.
Unit of analysis issues
The unit of analysis was the participant.
Dealing with missing data
We planned to request further information from primary inves-
tigators when required, but as the only included study was pub-
lished in 1992, we did not contact study authors (Tamaoki 1992).
Assessment of heterogeneity
We planned to describe heterogeneity between study results and
to use the Chi2 test to see if it reached statistical significance. We
would have considered heterogeneity as significant if the P value
was less than 0.10 (Higgins 2011). We also planned to use the I
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2 statistic when heterogeneity was categorised in such a way that
a value less than 25% was considered low, around 50% was con-
sidered moderate and over 75% was considered high for hetero-
geneity (Higgins 2003). As only one eligible study was identified,
assessment of heterogeneity was not applicable.
Assessment of reporting biases
Ifmore than 10 eligible studies were found, wewould have assessed
publication bias by using a funnel plot. We intended to investigate
and report on any cases of selective reporting.
Data synthesis
For the dichotomous outcome variables of each individual study,
we had planned to calculate odds ratios (ORs) using a modified
intention-to-treat (ITT) analysis. This analysis assumes that chil-
dren not available for outcome assessment have not improved (and
probably represents a conservative estimate of effect). An initial
qualitative comparison of all individually analysed studies exam-
ines whether pooling of results (meta-analysis) is reasonable. This
would take into account differences in study populations, inclu-
sion/exclusion criteria, interventions, outcome assessments and es-
timated effect size.
Results from studies that met the inclusion criteria and reported
any of the outcomes of interest were to be included in subsequent
meta-analyses.We planned to calculate the summaryORand 95%
CI (fixed-effect model) (RevMan 2014).
We planned to use data from parallel studies only (not from cross-
overs). We planned to calculate number needed to treat for an
additional beneficial outcome (NNTB) from the pooled OR and
its 95% CI applied to a specified baseline risk by using an online
calculator (Cates 2003). If studies reported outcomes based on
different measurement scales, we would have estimated standard-
ised mean differences (SMDs).
Subgroup analysis and investigation of heterogeneity
We planned the following a priori subgroup analyses.
• Children (≤ 18 years of age) and adults (> 18 years of age).
• Severity of bronchiectasis (based on FEV1: > 80% classified
as mild, 50% to 79% classified as moderate, 30% to 49%
classified as severe, < 30% classified as very severe).
We would have described and explored heterogeneity between
study results. We had planned to include the 95% CI estimated
by using a random-effects model when we had concerns about
statistical heterogeneity.
Sensitivity analysis
We also planned sensitivity analyses to assess the impact of poten-
tially important factors on overall outcomes.
• Variation in inclusion criteria.
• Differences in medications used in intervention and
comparison groups.
• Differences in outcome measures.
• Analysis using a random-effects model.
• Analysis by treatment received.
• Analysis by ITT.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
The Airways Group specialised register/literature search per-
formed in October 2008 and October 2009 yielded 173 (153 and
20 respectively) references.We found no RCTs that focused specif-
ically on adults or children with bronchiectasis. We identified two
publications that were considered for inclusion in this review. We
included one study (Tamaoki 1992); and we excluded the second
study (Llewellyn-Jones 1995), which did not meet eligibility cri-
teria.
The latest search for this update was performed in September 2015
and yielded 104 additional potential studies, but none met our
eligibility criteria (Figure 1); therefore, the results of this review
remain unchanged.
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Figure 1. Study flow diagram: review update.
Included studies
We identified no studies that focused solely on bronchiectasis in
adults or children. However, we included a single, small study
on 25 adults with chronic lung disease, including eight with
bronchiectasis (32%), as the two additional chronic lung disease
conditions in the study led to bronchiectasis, and bronchorrhoea
is a key clinical feature of bronchiectasis. Tamaoki and colleagues
(Tamaoki 1992) examined the short-term effects (14 days) of in-
haled indomethacin compared with placebo on sputum and blood
indices, dyspnoea scale and lung function in 25 adultswith chronic
lung disease (eight with bronchiectasis (32%), 12 with chronic
bronchitis and five with diffuse panbronchiolitis). We have pro-
vided details of this study in theCharacteristics of included studies
table.
Excluded studies
We excluded one study (Llewellyn-Jones 1995), as it was not a
randomised controlled trial.
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Risk of bias in included studies
Overall we assessed the sole included study (Tamaoki 1992) to
be at high risk of bias, as detailed in the ’Risk of bias’ table and
summarised below.
Allocation
The doctor responsible for allocating treatment groups was not
blinded (but was not involved in follow-up or data analysis). This
approach does not fulfill the criteria for adequate allocation con-
cealment and is considered to present high risk of selection bias.
Blinding
Participants and investigators responsible for disease follow-up and
data analysis were blinded, representing low risk of performance
and detection bias.
Incomplete outcome data
Data were complete for all participants.
Selective reporting
We identified no selective reporting bias in the study and consider
it to present low risk.
Other potential sources of bias
We identified no other potential sources of bias. However, data
analysis did not distinguish participants with bronchiectasis from
other respiratory groups, other than for sputum production. We
consider this to represent an unclear risk of bias.
Effects of interventions
Short-term effects
The primary outcome (MD in bronchiectasis severity control,
QOL, cough scores) was not reported in the included study.
Respiratory symptoms
The only clinical data reported consisted of the Borg score, which
showed significant differences between groups (MD -1.90, 95%
CI -3.15 to -0.65; Analysis 1.1).
Lung function
We noted no significant differences between groups for FEV1 %
predicted at the end of the study (MD -2.90%, 95% CI -13.30 to
7.50; Analysis 1.2) nor for vital capacity (VC) % predicted (MD
-2.90%, 95% CI -10.58 to 4.78; Analysis 1.3).
Other indices
For sputum indices, we found a significant decrease in wet weight
of sputum at the end of the study in the indomethacin group
compared with the placebo group (MD -75.00 g/day; 95% CI -
134.61 to -15.39; Analysis 1.4) but no difference in bacterial load
per gram of sputum (MD -0.30, 95% CI -1.71 to 1.11; Analysis
1.5).
For blood indices, we found no significant differences between
groups for erythrocyte sedimentation rate (ESR) (MD -2.00 mm/
h, 95% CI -13.42 to 9.42; Analysis 1.6) nor for total white
cell count (MD -400.00 cells/mL, 95% CI -1654.94 to 854.94;
Analysis 1.7).
Adverse events
Investigators reported no adverse events.
D I S C U S S I O N
Summary of main results
Data from one small, short-term (14-day) study of 25 adults
with chronic lung disease (12 with chronic bronchitis, eight with
bronchiectasis and five with panbronchiolitis) suggest that in-
haled indomethacin (a type of non-steroid anti-inflammatory drug
(NSAID)) was significantly beneficial in reducing sputum pro-
duction compared with placebo. The clinically important differ-
ence for bronchiectasis on the Borg scale is unknown, but that
for chronic obstructive pulmonary disease (COPD) is 1 unit (Ries
2005); thus the difference between groups for dyspnoea (mean
difference (MD) -1.90, 95% confidence interval (CI) -3.15 to -
0.65) is likely to be clinically important.
Investigators reported no differences between groups for lung
function nor for blood indices.
Overall completeness and applicability of
evidence
The sole small study included with its limited number of partic-
ipants with bronchiectasis (n = 8; 32%) limits definitive conclu-
sions.
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We identified no randomised controlled trials of inhaled NSAIDs
in children with bronchiectasis.
Quality of the evidence
The sole included study in this review (Tamaoki 1992) was dou-
ble-blind and randomised, although allocation of concealment re-
mains unknown. Overall, we judged the quality of the evidence
to be low. We downgraded the score two-fold on the basis of (1)
imprecision of results, caused by the small sample size, and (2)
indirect evidence, based on collective analysis of data from three
disease states; hence bronchiectasis-specific data are unknown.
Potential biases in the review process
This review has been conducted in accordance with the published
protocol. We did not contact the authors (for bronchiectasis-spe-
cific data) of the one included study, Tamaoki 1992, due to the age
of the study and the small number of participants with bronchiec-
tasis (n = 8). Such data would be unlikely to change the final con-
clusions of this review.
Agreements and disagreements with other
studies or reviews
The Cochrane review of oral NSAIDs for cystic fibrosis concluded
that NSAIDs are likely to slow the progression of lung disease
(Lands 2013). Review authors reported no data on sputum pro-
duction or dyspnoea. The Cochrane review of oral NSAIDs for
bronchiectasis (Kapur 2007) identified no relevant studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although a single study has shown some benefit for short-term
use of inhaled indomethacin in adults with chronic lung dis-
ease (including participants with bronchiectasis and those at risk
of bronchiectasis), evidence is currently insufficient to support
or refute the use of inhaled NSAIDs in children or adults with
bronchiectasis. NSAIDs may be beneficial in the immediate term
for reducing sputumproduction.However, there were too fewpar-
ticipants with bronchiectasis in the included study, and the dura-
tion of treatment was too short, to provide adequate information
on beneficial or adverse effects of inhaled NSAIDs in adults with
bronchiectasis. No data are currently available on the effectiveness
of inhaled NSAIDs in children with bronchiectasis.
Implications for research
Data presented in the only study included in this review indicate
that a double-blind, randomised, placebo-controlled trial is war-
ranted to investigate short-term (≤ 12 months) and long-term (>
one year) beneficial and adverse effects of inhaledNSAIDs for both
adults and children with bronchiectasis. Randomised controlled
trials should investigate children and adults separately and should
include data as highlighted in the Types of outcome measures sec-
tion of this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Tamaoki 1992
Methods Double-blind, randomised, placebo-controlled trial
Pulmonary function was assessed by a change in VC and FEV1 before treatment (day 0)
and on day 14. Quality of life was assessed by the Borg ratio scale for questions related
to breathlessness and dyspnoea
Sputumwas analysed for change in production (g/day), cyclo-oxygenase products (PGE2 ,
PGF2a , 6-oxo-PGF1a , TxB2) and microbiological culture
Statistical analysis: data were expressed as means ± SEM. Two-way analysis of variance
and Student’s paired t test were used for normally distributed variables. The Newman-
Keuls test was used for multiple comparisons. A P value less than 0.05 was considered
statistically significant
Participants 25 adults (age 29 to 78 years) with a diagnosis of chronic lung disease (chronic bronchitis
(N = 12), diffuse panbronchiolitis (N = 5) or bronchiectasis (N = 8)) and bronchorrhoea
of at least 4 weeks. Eight of the 25 participants had bronchiectasis, but all had symptoms
of bronchiectasis and 21 had chronic colonisation with respiratory pathogens present in
the adults with bronchiectasis - 17 had Pseudomonas aeruginosa, 3Haemophilus influenzae
and 1 Staphylococcus aureus. Of the 8 participants with bronchiectasis, 4 were allocated
to the indomethacin group and 4 to the placebo group. All had no history of respiratory
allergy
Interventions Treatment group 1: inhaled indomethacin, 2 mL aerosol preparation of 1.2 µg/mL in
saline 3 times daily for 14 days
Treatment group 2: inhaled placebo, 2 mL aerosolised saline alone 3 times daily for 14
days
Method of delivery: nebuliser delivering aerosolised particles with a median particle
diameter of 4.5 to 5 µm
Outcomes Data for all 3 disease states were analysed collectively.Outcomes were sputum indices (%
solid composition, sputum bacterial density and inflammatory markers - prostaglandin
E2, PGF2a , 6-oxo-PGF1a , TxB2), Borg score ratio scale for breathlessness and dyspnoea,
WCC, ESR and spirometry
The only outcome for which results were reported separately for participants with
bronchiectasis was effect on sputum production
Notes We elected to include all outcomes, as although not all participants had the diagnosis of
bronchiectasis, the additional 2 diseases (chronic bronchitis and panbronchiolitis) over-
lap with bronchiectasis and eventually can lead to bronchiectasis. Furthermore, the large
number colonised with bacteria, especially with Pseudomonas, indicates that bronchiec-
tasis would have been likely to be identified if a multi-detector high-resolution CT scan
had been performed on all participants
Risk of bias
Bias Authors’ judgement Support for judgement
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Tamaoki 1992 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) High risk The doctor responsible for allocating treat-
ment groups was not blinded but was not
involved in follow-up or data analysis
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators responsible for disease follow-
up and data analysis were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data were complete for all outcomes
Selective reporting (reporting bias) Low risk We identified no selective reporting
Other bias Unclear risk We identified no other potential sources of
bias. However, data analysis did not distin-
guish individuals with bronchiectasis from
people with other respiratory disease
CT: computed tomography.
ESR: erythrocyte sedimentation rate.
FEV1: forced expiratory volume in one second.
6-oxo-PGF1a: 6-oxo-prostaglandin F1 alpha.
PGE2: prostaglandin E2.
PGF2a : prostaglandin F2 alpha.
SEM: standard error of the mean.
TxB2 : thromboxane B2.
VC: vital capacity.
WCC: white cell count.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Llewellyn-Jones 1995 Study using oral indomethacin
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D A T A A N D A N A L Y S E S
Comparison 1. NSAID versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Borg score 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 FEV1 % predicted (end of
study)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 VC % predicted (end of study) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Wet weight of sputum at end of
study (g/day)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Bacterial load of sputum at end
of study (Log10 cfu/g)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 ESR at end of study (mm/h) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 White cell count at end of study
(per mm3)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 NSAID versus placebo, Outcome 1 Borg score.
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 NSAID versus placebo
Outcome: 1 Borg score
Study or subgroup Indomethacin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 4.5 (1.44) 12 6.4 (1.73) -1.90 [ -3.15, -0.65 ]
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours indomethacin Favours placebo
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Analysis 1.2. Comparison 1 NSAID versus placebo, Outcome 2 FEV1 % predicted (end of study).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 NSAID versus placebo
Outcome: 2 FEV1 % predicted (end of study)
Study or subgroup Indomethacin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 72.7 (12.98) 12 75.6 (13.51) -2.90 [ -13.30, 7.50 ]
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours indomethacin Favours placebo
Analysis 1.3. Comparison 1 NSAID versus placebo, Outcome 3 VC % predicted (end of study).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 NSAID versus placebo
Outcome: 3 VC % predicted (end of study)
Study or subgroup Indomethacin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 82.6 (8.65) 12 85.5 (10.74) -2.90 [ -10.58, 4.78 ]
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours indomethacin Favours placebo
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Analysis 1.4. Comparison 1 NSAID versus placebo, Outcome 4 Wet weight of sputum at end of study
(g/day).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 NSAID versus placebo
Outcome: 4 Wet weight of sputum at end of study (g/day)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 95 (75.72) 12 170 (76.21) -75.00 [ -134.61, -15.39 ]
-100 -50 0 50 100
Favours Indomethacin Favours placebo
Analysis 1.5. Comparison 1 NSAID versus placebo, Outcome 5 Bacterial load of sputum at end of study
(Log10 cfu/g).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 NSAID versus placebo
Outcome: 5 Bacterial load of sputum at end of study (Log10 cfu/g)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 7.8 (2.16) 12 8.1 (1.39) -0.30 [ -1.71, 1.11 ]
-4 -2 0 2 4
Favours indomethacin Favours placebo
16Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 NSAID versus placebo, Outcome 6 ESR at end of study (mm/h).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 NSAID versus placebo
Outcome: 6 ESR at end of study (mm/h)
Study or subgroup Indomethacin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 22 (10.8) 12 24 (17.32) -2.00 [ -13.42, 9.42 ]
-100 -50 0 50 100
Favours Indomethacin Favours placebo
Analysis 1.7. Comparison 1 NSAID versus placebo, Outcome 7White cell count at end of study (per mm3).
Review: Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Comparison: 1 NSAID versus placebo
Outcome: 7 White cell count at end of study (per mm
3
)
Study or subgroup Indomethcin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tamaoki 1992 13 6500 (1442) 12 6900 (1732.1) -400.00 [ -1654.94, 854.94 ]
-1000 -500 0 500 1000
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. Search methods used up to 2010
Electronic searches
We used the following topic search strategy to identify the relevant randomised controlled trials listed in the electronic databases:
(“bronchiectasis” OR “suppurative lung disease” as (textword) or (MeSH )) AND (“inhaled” OR “nebulise” OR “nebulised” as
(textword) or (MeSH )) AND (“anti-inflammatory” OR “diclofenac” OR “etodolac” OR “ketorolac” OR “sulindac” OR “tolmentin”
OR “diflunisal” OR “salsalate” OR “meloxicam”OR “piroxicam”OR “flurbiprofen”OR “Ibupropen”OR “ketoprofen”OR “naproxen”
OR “oxaprozin” OR “indomethacin” OR “COX2 inhibitors” OR “celecoxib” OR “rofecoxib” OR “valdecoxib”) as (textword) or
(MeSH)
We identified trials from the following sources.
• Cochrane Airways Group Trials Register.
• Cochrane Central Register of Controlled Trials (CENTRAL) (2009, Issue 3).
• MEDLINE (1966 to present).
• OLDMEDLINE (1950 to 1965).
• EMBASE (1980 to present).
For MEDLINE, OLDMEDLINE and EMBASE, we combined the topic search strategy with the RCT search filter as outlined in the
Airways Group module.
Searching other resources
We also searched the references in relevant publications. We planned to communicate with the authors of trials included in the review,
when necessary.
Appendix 2. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Bronchiectasis search
• 1. exp Bronchiectasis/
• 2. bronchiect$.mp.
• 3. bronchoect$.mp.
• 4. kartagener$.mp.
• 5. (ciliary adj3 dyskinesia).mp.
• 6. (bronchial$ adj3 dilat$).mp.
• 7. or/1-6
Filter to identify RCTs
• 1. exp “clinical trial [publication type]”/
• 2. (randomized or randomised).ab,ti.
• 3. placebo.ab,ti.
• 4. dt.fs.
• 5. randomly.ab,ti.
• 6. trial.ab,ti.
• 7. groups.ab,ti.
• 8. or/1-7
• 9. Animals/
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• 10. Humans/
• 11. 9 not (9 and 10)
• 12. 8 not 11
The MEDLINE strategy and the RCT filter are adapted to identify trials in other electronic databases.
Appendix 3. Search strategy to identify relevant trial reports from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Inflammatory Agents, Non-Steroidal
#6 anti NEXT inflammat*
#7 NSAID*
#8 diclofenac
#9 etodolac
#10 ketorolac
#11 sulindac
#12 diflunisal
#13 salsalate
#14 meloxicam
#15 piroxicam
#16 flurbiprofen
#17 Ibuprofen
#18 ketoprofen
#19 naproxen
#20 oxaprozin
#21 indometacin
#22 tolmetin
#23 MeSH DESCRIPTOR Cyclooxygenase 2 Inhibitors
#24 cyclooxygenase*
#25 cox NEXT 2
#26 celecoxib
#27 rofecoxib
#28 valdecoxib
#29 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #
20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28
#30 #4 AND #29
[Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case,
bronchiectasis.]
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WH A T ’ S N E W
Last assessed as up-to-date: 22 September 2015.
Date Event Description
28 September 2015 New search has been performed The latest search was conducted on 28 September
2015. Minor amendments have been made to the re-
view for consistency with updated guidelines of the
Cochrane Airways Group
28 September 2015 New citation required but conclusions have not
changed
No new studies were identified for this update. The
final conclusion remains unchanged
C O N T R I B U T I O N S O F A U T H O R S
SP and AC updated the review. JU and SY contributed to editing of the update.
D E C L A R A T I O N S O F I N T E R E S T
None of the review authors have reported any conflict of interest.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal [∗administration & dosage]; Bronchiectasis [∗drug therapy];
Dyspnea [drug therapy]; Sputum [secretion]
MeSH check words
Adult; Child; Humans
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